NRx Pharmaceuticals, Inc. – NASDAQ:NRXP
Founder-led company
NRx Pharmaceuticals stock price today
$2.53
+1.01
+67.55%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 15 hours
NRx Pharmaceuticals stock price monthly change
-39.11%
month
NRx Pharmaceuticals stock price quarterly change
-39.11%
quarter
NRx Pharmaceuticals stock price yearly change
+218.56%
year
NRx Pharmaceuticals key metrics
Market Cap | 17.53M |
Enterprise value | N/A |
P/E | -1.11 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 5.50 |
PEG ratio | -0.01 |
EPS | -0.98 |
Revenue | N/A |
EBITDA | -24.13M |
Income | -25.63M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNRx Pharmaceuticals stock price history
NRx Pharmaceuticals stock forecast
NRx Pharmaceuticals financial statements
| Jun 2023 | 0 | -8.71M | |
|---|---|---|---|
| Sep 2023 | 0 | -6.06M | |
| Dec 2023 | 8K | -4.33M | -54150% |
| Mar 2024 | 0 | -6.52M |
| Dec 2023 | 8K | -4.33M | -54150% |
|---|---|---|---|
| Mar 2024 | 0 | -6.52M | |
| Oct 2025 | 0 | -4.07M | |
| Dec 2025 | 0 | -4.07M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 19809000 | 22.61M | 114.18% |
|---|---|---|---|
| Sep 2023 | 13110000 | 19.32M | 147.42% |
| Dec 2023 | 7315000 | 19.04M | 260.4% |
| Mar 2024 | 3788000 | 18.85M | 497.81% |
| Jun 2023 | -7.81M | 2K | 6.27M |
|---|---|---|---|
| Sep 2023 | -4.56M | -2K | -1.50M |
| Dec 2023 | -3.19M | 1K | -1.11M |
| Mar 2024 | -3.67M | 0 | 395K |
NRx Pharmaceuticals alternative data
| Aug 2023 | 2 |
|---|---|
| Sep 2023 | 2 |
| Oct 2023 | 2 |
| Nov 2023 | 2 |
| Dec 2023 | 2 |
| Jan 2024 | 2 |
| Feb 2024 | 2 |
| Mar 2024 | 2 |
| Apr 2024 | 2 |
| May 2024 | 2 |
| Jun 2024 | 2 |
| Jul 2024 | 2 |
NRx Pharmaceuticals other data
1.09%
-3.57%
of NRXP is owned by hedge funds
18
-13
716.32K
-2.38M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2024 | 40000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | JAVITT JONATHAN C director, 10 perc.. | Common Stock | 40,000 | $1.17 | $46,800 | ||
Purchase | JAVITT JONATHAN C director, 10 perc.. | Common Stock | 40,000 | $1.17 | $46,800 | ||
Purchase | GOROVITZ AARON director | Common Stock, par value $0.001 per share | 35,000 | $0.32 | $11,200 | ||
Purchase | HURVITZ CHAIM director | Common Stock, par value $0.001 per share | 70,000 | $0.29 | $20,160 | ||
Purchase | JAVITT JONATHAN C director, 10 perc.. | Common Stock | 100,000 | $0.33 | $33,000 | ||
Purchase | JAVITT JONATHAN C director, 10 perc.. | Common Stock | 100,000 | $0.33 | $33,000 | ||
Purchase | JAVITT JONATHAN C director, 10 perc.. | Common Stock | 200,000 | $0.32 | $64,400 | ||
Purchase | JAVITT JONATHAN C director, 10 perc.. | Common Stock | 200,000 | $0.32 | $64,400 | ||
Purchase | WILLARD STEPHEN H director: CHIEF EXECUTIVE OFFICER | Common Stock, par value $0.001 per share | 50,000 | $1.17 | $58,500 | ||
Purchase | VAN VOORHEES SETH director: CHIEF FINANCIAL OFFICER | Common Stock, par value $0.001 per share | 30,000 | $1.1 | $33,000 |
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 1 Apr 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 14 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 14 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Jonathan C. Javitt M.D., M.P.H. (1957) Co-Founder, Chairman & Chief Executive Officer | $471,050 |
Mr. Robert Besthof M.I.M. (1966) Head of Operations & Chief Commercial Officer and Patient Officer | $214,380 |
-
What's the price of NRx Pharmaceuticals stock today?
One share of NRx Pharmaceuticals stock can currently be purchased for approximately $2.53.
-
When is NRx Pharmaceuticals's next earnings date?
Unfortunately, NRx Pharmaceuticals's (NRXP) next earnings date is currently unknown.
-
Does NRx Pharmaceuticals pay dividends?
No, NRx Pharmaceuticals does not pay dividends.
-
How much money does NRx Pharmaceuticals make?
NRx Pharmaceuticals has a market capitalization of 17.53M.
-
What is NRx Pharmaceuticals's stock symbol?
NRx Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "NRXP".
-
What is NRx Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of NRx Pharmaceuticals?
Shares of NRx Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are NRx Pharmaceuticals's key executives?
NRx Pharmaceuticals's management team includes the following people:
- Dr. Jonathan C. Javitt M.D., M.P.H. Co-Founder, Chairman & Chief Executive Officer(age: 68, pay: $471,050)
- Mr. Robert Besthof M.I.M. Head of Operations & Chief Commercial Officer and Patient Officer(age: 59, pay: $214,380)
-
Is NRx Pharmaceuticals founder-led company?
Yes, NRx Pharmaceuticals is a company led by its founder Dr. Jonathan C. Javitt M.D., M.P.H..
-
How many employees does NRx Pharmaceuticals have?
As Jul 2024, NRx Pharmaceuticals employs 2 workers.
-
When NRx Pharmaceuticals went public?
NRx Pharmaceuticals, Inc. is publicly traded company for more then 7 years since IPO on 4 Dec 2017.
-
What is NRx Pharmaceuticals's official website?
The official website for NRx Pharmaceuticals is nrxpharma.com.
-
Where are NRx Pharmaceuticals's headquarters?
NRx Pharmaceuticals is headquartered at 1201 Orange Street, Wilmington, DE.
-
How can i contact NRx Pharmaceuticals?
NRx Pharmaceuticals's mailing address is 1201 Orange Street, Wilmington, DE and company can be reached via phone at +48 42546134.
NRx Pharmaceuticals company profile:
NRx Pharmaceuticals, Inc.
nrxpharma.comExchange:
NASDAQ
Full time employees:
2
Industry:
Biotechnology
Sector:
Healthcare
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
1201 Orange Street
Wilmington, DE 19801
Wilmington, DE 19801
CIK: 0001719406
ISIN: US6294441000
CUSIP: 089482103
